Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 211, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2020.112999
Keywords
HIF-2; Agonist; Binding mode; Molecular dynamic simulations
Categories
Funding
- National Natural Science Foundation of China [81773571]
- Jiangsu Province Funds for Excellent Young Scientists [BK20170088]
Ask authors/readers for more resources
This study involves the identification and evaluation of HIF-2 agonists, M1001 and its analog M1002, highlighting their potential as novel therapeutic agents for human oxygen metabolism. The use of molecular dynamics simulations allowed for the proposal of a plausible binding mode for these agonists, complemented by the synthesis and evaluation of compounds to verify the proposed mode. Compound 10 demonstrated improved agonistic activity and reduced toxicity compared to M1002, indicating its potential for further development.
Hypoxia-inducible factor-2 (HIF-2), a heterodimeric transcriptional protein consisting of HIF-2 alpha and aryl hydrocarbon receptor nuclear translocator (ARNT) subunits, has a broad transcriptional profile that plays a vital role in human oxygen metabolism. M1001, a HIF-2 agonist identified by high-throughput screening (HTS), is capable of altering the conformation of Tyr281 of the HIF-2 alpha PAS-B domain and enhancing the affinity of HIF-2 alpha and ARNT for transcriptional activation. M1002, an analog of M1001, shows improved efficacy than M1001. However, the cocrystal structure of M1001 and HIF-2 has some defects in revealing the agonist binding mode due to the relatively low resolution, while the binding mode of M1002 remained unexplored. To in-depth understand agonist binding profiles, herein, the molecular dynamic (MD) simulations was applied to construct a stable agonist-protein model, and a possible binding mode was proposed through the analysis of the binding free energy and hydrogen bonding of the simulation results. Nine compounds were then synthesized and evaluated to verify the proposed binding mode. Among them, compound 10 manifested improved agonistic activity and reduced toxicity compared to M1002. This study provides deep insight into the binding mode of such HIF-2 agonists, which would be useful for designing novel agonists for HIF-2. (C) 2020 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available